Active	Status	Sponsor type	Region	Phase	Filter
2 Active 12 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
epetraborole (AN3365) / AN2 Therap
NCT05327803: Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease	Terminated	2/3	177	Japan, US, RoW	Epetraborole, AN2-501971, Placebo	AN2 Therapeutics, Inc	MAC Lung Disease, Treatment Refractory MAC Lung Disease	12/24	12/24
NCT05995444: A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects	Completed	1	24	US	Epetraborole and matching placebo, Therapeutic, Epetraborole, Supratherapeutic, Placebo, Placebo Control, Moxifloxacin, Positive Control	AN2 Therapeutics, Inc	Healthy Volunteers	07/23	08/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
epetraborole (AN3365) / AN2 Therap
NCT05327803: Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease	Terminated	2/3	177	Japan, US, RoW	Epetraborole, AN2-501971, Placebo	AN2 Therapeutics, Inc	MAC Lung Disease, Treatment Refractory MAC Lung Disease	12/24	12/24
NCT05995444: A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects	Completed	1	24	US	Epetraborole and matching placebo, Therapeutic, Epetraborole, Supratherapeutic, Placebo, Placebo Control, Moxifloxacin, Positive Control	AN2 Therapeutics, Inc	Healthy Volunteers	07/23	08/23